KR20210131329A - 카르바메이트 유도체 및 이의 용도 - Google Patents
카르바메이트 유도체 및 이의 용도 Download PDFInfo
- Publication number
- KR20210131329A KR20210131329A KR1020217025978A KR20217025978A KR20210131329A KR 20210131329 A KR20210131329 A KR 20210131329A KR 1020217025978 A KR1020217025978 A KR 1020217025978A KR 20217025978 A KR20217025978 A KR 20217025978A KR 20210131329 A KR20210131329 A KR 20210131329A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- compound
- optionally substituted
- heterocycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 **C(C(O*)=O)OC(NC(*)*)=O Chemical compound **C(C(O*)=O)OC(NC(*)*)=O 0.000 description 9
- MPLZWEBMAZIJCN-XJKSGUPXSA-N CC(C)OC([C@@H](C[n]1ncnc1)OC(N[C@@H](C)c(cc1)ccc1OCC(F)(F)F)=O)=O Chemical compound CC(C)OC([C@@H](C[n]1ncnc1)OC(N[C@@H](C)c(cc1)ccc1OCC(F)(F)F)=O)=O MPLZWEBMAZIJCN-XJKSGUPXSA-N 0.000 description 1
- DRNINDBIKNRSAD-BLLLJJGKSA-N CC(C)OC([C@@H](Cc1ncccn1)OC(N[C@@H](C)c1ccc(C(F)(F)F)cc1Cl)=O)=O Chemical compound CC(C)OC([C@@H](Cc1ncccn1)OC(N[C@@H](C)c1ccc(C(F)(F)F)cc1Cl)=O)=O DRNINDBIKNRSAD-BLLLJJGKSA-N 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N CC(c(cc1)ccc1O)=O Chemical compound CC(c(cc1)ccc1O)=O TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- WLTPFXQNFLAKQT-UHFFFAOYSA-N CC(c(cc1)ccc1OCC(F)(F)F)=O Chemical compound CC(c(cc1)ccc1OCC(F)(F)F)=O WLTPFXQNFLAKQT-UHFFFAOYSA-N 0.000 description 1
- BDMFEFZOOOYCKN-UHFFFAOYSA-N CCC[n]1nccc1 Chemical compound CCC[n]1nccc1 BDMFEFZOOOYCKN-UHFFFAOYSA-N 0.000 description 1
- FLNMQGISZVYIIK-UHFFFAOYSA-N CC[n]1nccc1 Chemical compound CC[n]1nccc1 FLNMQGISZVYIIK-UHFFFAOYSA-N 0.000 description 1
- FEOIYPLRWRCSMS-UHFFFAOYSA-N CC[n]1ncnc1 Chemical compound CC[n]1ncnc1 FEOIYPLRWRCSMS-UHFFFAOYSA-N 0.000 description 1
- RILVNLMOTMFTMQ-UHFFFAOYSA-N CCc1ncccn1 Chemical compound CCc1ncccn1 RILVNLMOTMFTMQ-UHFFFAOYSA-N 0.000 description 1
- VBMYVQSSXSALKH-UHFFFAOYSA-N CN(C)C[n]1ncnc1 Chemical compound CN(C)C[n]1ncnc1 VBMYVQSSXSALKH-UHFFFAOYSA-N 0.000 description 1
- FOEMIZSFFWGXHX-UHFFFAOYSA-N CSc1ncccn1 Chemical compound CSc1ncccn1 FOEMIZSFFWGXHX-UHFFFAOYSA-N 0.000 description 1
- ARKYSTIBVFZKEM-QMMMGPOBSA-N C[C@@H](c(cc1)ccc1OCC(F)(F)F)N=C=O Chemical compound C[C@@H](c(cc1)ccc1OCC(F)(F)F)N=C=O ARKYSTIBVFZKEM-QMMMGPOBSA-N 0.000 description 1
- AJWOZJMEMDMJKC-CHNSCGDPSA-N C[C@@H](c(cc1)ccc1OCC(F)(F)F)N[S@@](C(C)(C)C)=O Chemical compound C[C@@H](c(cc1)ccc1OCC(F)(F)F)N[S@@](C(C)(C)C)=O AJWOZJMEMDMJKC-CHNSCGDPSA-N 0.000 description 1
- SQDYNHWWIVDWAV-YFKPBYRVSA-N C[C@@H](c1ccc(C(F)(F)F)cc1Cl)N Chemical compound C[C@@H](c1ccc(C(F)(F)F)cc1Cl)N SQDYNHWWIVDWAV-YFKPBYRVSA-N 0.000 description 1
- UIZMGORJDNLWOE-LURJTMIESA-N C[C@@H](c1ccc(C(F)(F)F)cc1Cl)N=C=O Chemical compound C[C@@H](c1ccc(C(F)(F)F)cc1Cl)N=C=O UIZMGORJDNLWOE-LURJTMIESA-N 0.000 description 1
- MERXNOMVLHEZHE-YFKPBYRVSA-N C[I](C1)NC[C@H]1[I]=C Chemical compound C[I](C1)NC[C@H]1[I]=C MERXNOMVLHEZHE-YFKPBYRVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796724P | 2019-01-25 | 2019-01-25 | |
| US62/796,724 | 2019-01-25 | ||
| PCT/EP2020/051836 WO2020152361A1 (en) | 2019-01-25 | 2020-01-24 | Carbamate derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210131329A true KR20210131329A (ko) | 2021-11-02 |
Family
ID=69375331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217025978A Abandoned KR20210131329A (ko) | 2019-01-25 | 2020-01-24 | 카르바메이트 유도체 및 이의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220098159A1 (https=) |
| EP (1) | EP3914351A1 (https=) |
| JP (1) | JP2022518526A (https=) |
| KR (1) | KR20210131329A (https=) |
| CN (1) | CN113660983A (https=) |
| AU (1) | AU2020211361A1 (https=) |
| BR (1) | BR112021014389A2 (https=) |
| CA (1) | CA3126495A1 (https=) |
| EA (1) | EA202192057A1 (https=) |
| IL (1) | IL284843A (https=) |
| MX (1) | MX2021008930A (https=) |
| SG (1) | SG11202107653RA (https=) |
| WO (1) | WO2020152361A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FI921595A7 (fi) * | 1991-04-17 | 1992-10-18 | American Home Prod | Rapamysiinikarbamaatteja |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| WO1999012534A1 (en) * | 1997-09-10 | 1999-03-18 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| US20020002200A1 (en) * | 2000-02-04 | 2002-01-03 | Bishwagit Nag | Novel diphenylethylene compounds |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| WO2017035413A2 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| JP2019512009A (ja) * | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| RU2720203C1 (ru) * | 2017-01-20 | 2020-04-27 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
-
2020
- 2020-01-24 BR BR112021014389-0A patent/BR112021014389A2/pt not_active Application Discontinuation
- 2020-01-24 KR KR1020217025978A patent/KR20210131329A/ko not_active Abandoned
- 2020-01-24 JP JP2021543144A patent/JP2022518526A/ja active Pending
- 2020-01-24 EA EA202192057A patent/EA202192057A1/ru unknown
- 2020-01-24 WO PCT/EP2020/051836 patent/WO2020152361A1/en not_active Ceased
- 2020-01-24 US US17/425,461 patent/US20220098159A1/en not_active Abandoned
- 2020-01-24 SG SG11202107653RA patent/SG11202107653RA/en unknown
- 2020-01-24 CA CA3126495A patent/CA3126495A1/en active Pending
- 2020-01-24 EP EP20702596.6A patent/EP3914351A1/en not_active Withdrawn
- 2020-01-24 CN CN202080024041.8A patent/CN113660983A/zh active Pending
- 2020-01-24 MX MX2021008930A patent/MX2021008930A/es unknown
- 2020-01-24 AU AU2020211361A patent/AU2020211361A1/en not_active Abandoned
-
2021
- 2021-07-14 IL IL284843A patent/IL284843A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3914351A1 (en) | 2021-12-01 |
| MX2021008930A (es) | 2021-11-04 |
| SG11202107653RA (en) | 2021-08-30 |
| EA202192057A1 (ru) | 2021-12-23 |
| JP2022518526A (ja) | 2022-03-15 |
| AU2020211361A1 (en) | 2021-08-19 |
| CA3126495A1 (en) | 2020-07-30 |
| US20220098159A1 (en) | 2022-03-31 |
| WO2020152361A1 (en) | 2020-07-30 |
| IL284843A (en) | 2021-08-31 |
| CN113660983A (zh) | 2021-11-16 |
| BR112021014389A2 (pt) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3661921B1 (en) | Selective inhibitors of nlrp3 inflammasome | |
| EP3983407B1 (en) | Sulfonylurea derivatives and uses thereof | |
| CN114641466B (zh) | 磺酰脲衍生物及其用途 | |
| WO2020157069A1 (en) | Amino heterocyclic compounds and uses thereof | |
| KR20210131329A (ko) | 카르바메이트 유도체 및 이의 용도 | |
| EP3983388A1 (en) | Sulfonamide derivatives and uses thereof | |
| JP2009500343A (ja) | 新規ヒドロキサム酸含有アミノ酸誘導体 | |
| HK40031620A (en) | Selective inhibitors of nlrp3 inflammasome | |
| HK40031620B (en) | Selective inhibitors of nlrp3 inflammasome | |
| US20250115558A1 (en) | Pyridazine derivatives and related uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PC1902 | Submission of document of abandonment before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1902 |